Why the study?
Overweight, obesity, and metabolic syndrome exert an activating effect on the sympathetic nervous system, increasing blood pressure and target-organ damage.
Does bisoprolol improve target organ protection in patients with arterial hypertension and concomitant obesity and metabolic syndrome?
Does bisoprolol improve target organ protection in patients with arterial hypertension and concomitant obesity and metabolic syndrome?
The review highlights the role of sympathetic overactivity in obesity-related hypertension and supports the use of bisoprolol for target organ protection in this population.
The review discusses the problem of overweight, obesity and metabolic syndrome and their activating effect on the sympathetic nervous system and the increase in blood pressure. Current epidemiological data on the prevalence of obesity and metabolic syndrome and trends in their occurrence in recent decades are presented, indicating the high significance of these disorders in modern health care and their important role in development of the overall disease burden. In accordance with the clinical guidelines, types of obesity are described with a special focus on its abdominal type, as a factor that increases cardiovascular risk. The mechanisms of sympathetic overactivity in obesity, including insulin resistance, hyperleptinemia, the effect of nonesterified fatty acids, obstructive sleep apnea and baroreflex impairment are considered in detail. In the second part of the paper experimental and clinical findings are presented indicating worsening of the hypertension mediated target-organ damage in the presence of concomitant obesity that emphases on the crucial role of amplified adrenergic stimuli in the formation of these disorders. The promoting effect of obesity and concomitant sympathetic nervous system overactivation on the development of left ventricular hypertrophy, endothelial dysfunction and vascular damage, renal dysfunction and cognitive decline are considered. Finally, body of evidence of high antihypertensive efficacy as well as prominent target organ protective features of the highly selective β 1 -blocker bisoprpolol are presented especially when it prescribed in patients with arterial hypertension and concomitant obesity and metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Кочетков et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: